AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$TWST

Green Paula sold $111K of TWST

Green Paula (SVP of Human Resources) sold 907 shares of Twist Bioscience Corp (TWST) at $122.62 ($0.11M total) on 2026-09-08.

Original reporting
SEC EDGAR · Green Paula
Published Sep 10, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed sale is modest and does not suggest a shift in company fundamentals.

02

Market read

Routine insider sell with limited trading relevance.

03

What to watch

Potential upcoming dilution or financing events not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: filing date 2026-09-10

Background

Form 4 filings disclose insider transactions; traders monitor them for signals of confidence.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

SVP of HR Green Paula sold 907 shares for $111K, reducing her stake to 117,014 shares.

Expected impact

No significant impact; price may stay flat or dip slightly on volume.

Evidence & confidence

The sale size is small relative to market cap and insider ownership; no change in control or strategic direction.

Market effects

Sector

None; HR insider activity does not affect biotech sector trends.

Regional

None; the filing is U.S.-based and limited to Twist Bioscience.

Global

Minimal; only relevant to investors tracking insider activity.

Counterpoint

What could challenge this read

If the insider is privy to upcoming negative news, the sale could foreshadow a downside.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech company listed on NASDAQ.

  • Insider
    Green Paula

    Senior Vice President of Human Resources.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min
SEP 16
$TWSTMed

Why is Twist Bioscience stock rallying today?

Twist Bioscience (TWST) stock rose 3.7% after joining Eli Lilly's TuneLab platform as a preferred antibody data provider. The deal supports Twist's AI-driven life science strategy, following record Q3 revenue and raised guidance. The stock is near its 52-week high, with NASDAQ and S&P 500 also gaining.

investing.com2 min